Entrada Therapeutics Inc (TRDA)

In the past six months, Entrada Therapeutics' stock price significantly decreased on May 7, 2026, due to initial data from the ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy. Prior to this, earnings reports generally led to modest positive stock movements. The FDA granted Rare Pediatric Disease Designation to ENTR-601-44 in December 2025.

As a clinical-stage biopharmaceutical company, Entrada Therapeutics does not have commercialized products or services subject to traditional consumer demand seasonality. The company's business model is focused on research and development, with revenue primarily derived from collaboration agreements. The company's progress and value are driven by clinical trial milestones, regulatory approvals, and strategic partnerships.

Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for intracellular pathways, utilizing its EEV platform for targeted delivery of therapeutics. The company's primary focus is on neuromuscular diseases, particularly Duchenne muscular dystrophy (DMD), with key programs including ENTR-601-44 and ENTR-601-45. Entrada is also exploring therapies for ocular diseases and investigating applications in immunology and oncology.

Entrada Therapeutics is headquartered in Boston, Massachusetts, which serves as its primary hub for research and development, clinical operations, and corporate administration. The company maintains a global outlook, with clinical trial operations designed to include international sites and engagement with global regulatory authorities and potential partners.

Entrada Therapeutics' brand reputation has been tied to its scientific advancements and clinical pipeline. The market's reaction to the initial Phase 1/2 ELEVATE-44-201 trial data for ENTR-601-44 on May 7, 2026, impacted its reputation, particularly among investors. The lower-than-expected dystrophin increase led to a substantial drop in stock price, affecting investor confidence.

Entrada Therapeutics is primarily owned by institutional shareholders, who hold 62.93% of the stock, and Entrada Therapeutics insiders, owning 88.27%. Major institutional owners include Baker Bros. Advisors Lp and MPM Asset Management Llc. Kush Parmar is the largest individual shareholder, owning 5.19 million shares, representing 13.37% of the company.